Lv53
908 积分 2024-10-09 加入
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
1天前
已完结
Managing early-onset type 2 diabetes in the individual and at the population level
19天前
已完结
Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once‐weekly basal insulin, in healthy participants: A randomized trial
20天前
已完结
Effectiveness of GLP‐1RA according to different type 2 diabetes phenotypes: A retrospective study
1个月前
已完结
Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
1个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study
1个月前
已完结
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes
1个月前
已关闭
Efficacy and safety benefits of HR17031, a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open‐label, randomised, parallel three‐arm, treat‐to‐target trial
1个月前
已完结
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
1个月前
已完结
The Acute and Chronic Effects of Betaxolol on Blood Pressure, Renin‐Aldosterone, and Renal Function in Essential Hypertension
1个月前
已完结
皖公网安备34019202002308
